适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Kidney cancerMetastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC) and with End-Stage Renal Disease (ESRD)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864MedDRA version: 22.0Level: HLTClassification code: 10038443Term: Renal failure and impairment Class: 10038359CTIS2023-505605-16-00Oncorena AB50
招募中
1 期
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid TumorsCTIS2022-500849-24-00Tolremo Therapeutics AG25
进行中（未招募）
1 期
A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomasarge Granular Lymphocytic Leukemia or Cytotoxic LymphomasMedDRA version: 20.0Level: LLTClassification code: 10029430Term: NK-cell leukemia Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065862Term: T-cell large granular lymphocytic leukemia Class: 10029104CTIS2023-503550-13-00Dren Bio Inc.116
进行中（未招募）
1 期
Effects of NT-0796 in Healthy Volunteers and Patients with Parkinson’s DiseaseMedDRA version: 21.1Level: LLTClassification code: 10013113Term: Disease Parkinson's Class: 10029205Parkinson's DiseaseCTIS2023-503203-29-00odthera Limited14
招募中
1 期
A Study of NB003 in Patients With Advanced MalignanciesCTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290